-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, RjgzTdHVdJD5gh0T+H4Msia6ErZAAPPQZttMybl7hRh7DOS8WbLmutNc84xPl6Jt EoUGrHwWOkLDx0mZ2U31gQ== 0001144204-04-005273.txt : 20040422 0001144204-04-005273.hdr.sgml : 20040422 20040422102146 ACCESSION NUMBER: 0001144204-04-005273 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20040422 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: ANIKA THERAPEUTICS INC CENTRAL INDEX KEY: 0000898437 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 043145961 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-45573 FILM NUMBER: 04747064 BUSINESS ADDRESS: STREET 1: 236 WEST CUMMINGS PARK CITY: WOBURN STATE: MA ZIP: 01801 BUSINESS PHONE: 6179326616 MAIL ADDRESS: STREET 1: 236 WEST CUMMINGS PARK CITY: WOBURN STATE: MA ZIP: 01801 FORMER COMPANY: FORMER CONFORMED NAME: ANIKA RESEARCH INC DATE OF NAME CHANGE: 19930309 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: AXIOM VENTURE ADVISORS INC CENTRAL INDEX KEY: 0001280246 IRS NUMBER: 061392417 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: 666 THIRD AVE CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: 2129353000 MAIL ADDRESS: STREET 1: C/O AXIOM VENTURE PARTNERS L P STREET 2: 185 ASYLUM ST CITY: HARTFORD STATE: CT ZIP: 06103 SC 13D/A 1 v02841_sc13da.txt SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13D-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13D-1(A) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13D-2(A) (AMENDMENT NO. 3)* ANIKA THERAPEUTICS, INC. - -------------------------------------------------------------------------------- (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE - -------------------------------------------------------------------------------- (Title of Class of Securities) 035255108 --------------------------------------------- (CUSIP Number) Frank J. Marco, Esq. Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. Connecticut Financial Center 157 Church Street New Haven, CT 06510 (203) 777-8200 - -------------------------------------------------------------------------------- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) April 12, 2004 --------------------------------------------- (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. |_| NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See ss. 240.13d-7(b) for other parties to whom copies are to be sent. *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). ================================================== CUSIP NO. 035255108 13D ================================================== - -------------------------------------------------------------------------------- 1 NAMES OF REPORTING PERSONS Axiom Venture Partners L.P. (the "Reporting Person") I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) 06-1392421 - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) |_| (b) |_| - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS N/A - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) |_| - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION State of Delaware - -------------------------------------------------------------------------------- NUMBER OF 7 SOLE VOTING POWER SHARES BENEFICIALLY 65,926 OWNED BY -------------------------------------------------------- EACH 8 SHARED VOTING POWER REPORTING PERSON 0 WITH -------------------------------------------------------- 9 SOLE DISPOSITIVE POWER 65,926 -------------------------------------------------------- 10 SHARED DISPOSITIVE POWER 0 - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 65,926 - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES |_| - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) .006% - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON PN - -------------------------------------------------------------------------------- Page 2 of 4 pages Item 1. Security and Issuer This Amendment No. 3 to Schedule 13D relates to the common stock, par value $0.01 per share (the "Common Stock"), of Anika Therapeutics, Inc., a Massachusetts corporation, whose principal executive officers are located at 160 New Boston Street, Woburn, Massachusetts 01801. The Reporting Person hereby amends its statement on Schedule 13D relating to the shares of Common Stock as set forth below. Item 5. Interest in Securities of the Issuer Items 5 of the statement on Schedule 13D filed by the Reporting Person on December 1, 1997 is hereby amended and restated to read as follows: (a) As of the date hereof, the Reporting Person is deemed to beneficially own, in the aggregate, 65,926 shares of Common Stock underlying stock options that are exercisable within 60 days of the date hereof. (b) Not applicable. (c) The following table sets forth all transactions with respect to the shares of Common Stock effected since the most recent filing on Schedule 13D by any of the Reporting Persons. NUMBER OF SHARES NAME DATE DISTRIBUTED - ---- ---- ----------- Axiom Venture Partners, L.P. 4/12/04 845,710 (d) Not applicable. (e) On April 12, 2004 the Reporting Person made a distribution of 845,710 shares of Common Stock (which amount included 3,020 shares of Common Stock received as a result of the issuance of dividends) to its general partner and its limited partners. As of April 12, 2004, the Reporting Person ceased to be the beneficial owner of more than five percent of the Common Stock. Page 3 of 4 pages SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: April 21, 2004 AXIOM VENTURE PARTNERS L.P. By: /s/ AXIOM VENTURE ASSOCIATES L.P. Axiom Venture Associates L.P. Its General Partner By: /s/ Samuel McKay Samuel McKay Page 4 of 4 pages -----END PRIVACY-ENHANCED MESSAGE-----